Pharma major Lupin on Thursday said that its facility in Vizag, Andhra Pradesh, has received the inspection closure report from the US health regulator.
The inspection for the facility was conducted by the United States Food and Drug Administration (USFDA) during January 13-17, the company said.
It informed stock exchanges of "the receipt of the establishment inspection report (EIR) from the United States Food and Drug Administration (USFDA) after closure of the inspection for its Vizag (Vishakhapatnam), India facility."